https://www.selleckchem.com/pr....oducts/upadacitinib.
954; 95 CI = 1.898-8.236; 0.001) and OS (HR = 5.330; 95 CI = 1.563-18.178; = 0.008). This retrospective study demonstrated an improved survival outcome for patients undergoing NACT + RS compared with those undergoing CCRT. Our findings seem to support the use of NACT before RS as an effective alternative option to CCRT standard therapy. This retrospective study demonstrated an improved survival outcome for patients undergoing NACT + RS compared with those undergoing CCRT. Our findings seem to support the use of NACT before R
Like
Comment
Share
